The Role of the Clinical and Molecular Assays in Prostate Cancer Detection

Abstract

To assess the correlation between the clinical and molecular assays in identify early and robust prostate cancer detection. Early detection, management of cancer and decision about the disease are important for beneficial treatment of prostate cancer. We used a computerized search of the Medline/ PubMed databases with the key words prostate cancer, biomarker, and early detection. Clinical management of cancer is facilitated by a conventional test such as prostate-specific antigen and digital rectal exam for application in clinical practice. Although these tests have significantly reduced the mortality with prostate cancer, but have some drawbacks and false positive rate. Fortunately, there are strong correlations between the clinical and molecular assays in identifying early and robust cancer detection, because molecular assays are less invasive and reliable. The use of genetic markers has the potential to providing useful prognostic or predictive information into clinically useful diagnostic tests to improve clinical decision-making and enhance therapeutic success. Different clinical and molecular assays are for detecting prostate cancer and use the biomarkers as potential tumor markers could be a useful predictor in the screening and monitoring to avoid over treatment prostate cancer.

Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment

“…Although genetic similarity is seen in the family, different responses to medical care and drugs, or different symptoms from asymptomatic to severe, can be observed in individuals in the family [38]. Apart from the complexity of the virus, the level of cytokine expression and immune response to the secretion of antibodies and macrophages are different in individuals in every disease.…”

Molecular miR-19a in Acute Myocardial Infarction: Novel Potential Indicators of Prognosis and Early Diagnosis

“…It has recently approved that microRNAs (miRNAs) are the major markers and ideal candidates for early diagnosis of AMI (Xiao et al, 2014). They are small non-coding RNAs of 18-24 nucleotides with the potential of regulating multiple targets and also some miRNAs can act on different targets at the same time (Mansouri, 2017). Different miRNAs inhibit gene expression by complementary sequences in the 3'-untranslated region (3'-UTR) of the target genes, of which is located on the long arm of chromosome 13 as a member of mircroRNA-17-92 cluster and its expression is associated with the development of pulmonary diseases and heart failure (Deng and Zhong, 2016).…”

“…The correlation between miR-19a concentrations and MI types in emergency medical services is not clear (Liu et al, 2018). MiRNAs are stable in whole blood, plasma, urine and have the key role in cell proliferation, angiogenesis differentiation and apoptosis (De Guire et al, 2013;Mansouri, 2017).…”

Consummated Review on Prostatitis

“…If the prostatitis is left untreated that leads to the chronic stage and later it causes enlargement associated hardening of the prostate gland that finally ends resulting in prostate cancer. Identification of the exact stage of prostate enlargement whether it is prostatitis or prostate cancer by a conventional test such as PSA and digital rectal exam for application in clinical practice [76]. There is a strong similarity among the clinical and molecular assays in identifying initially and robust cancer determination because molecular assays are less aggressive and reliable.…”